Epidrug mediated re-expression of miRNA targeting the HMGA transcripts in pituitary cells
- 405 Downloads
Transgenic mice overexpressing the high mobility group A (HMGA) genes, Hmga1 or Hmga2 develop pituitary tumours and their overexpression is also a frequent finding in human pituitary adenomas. In some cases, increased expression of HMGA2 but not that of HMGA1 is consequent to genetic perturbations. However, recent studies show that down-regulation of microRNA (miRNA), that contemporaneously target the HMGA1 and HMGA2 transcripts, are associated with their overexpression.
In a cohort of primary pituitary adenoma we determine the impact of epigenetic modifications on the expression of HMGA-targeting miRNA. For these miRNAs, chromatin immunoprecipitations showed that transcript down-regulation is correlated with histone tail modifications associated with condensed silenced genes. The functional impact of epigenetic modification on miRNA expression was determined in the rodent pituitary cell line, GH3. In these cells, histone tail, miRNA-associated, modifications were similar to those apparent in human adenoma and likely account for their repression. Indeed, challenge of GH3 cells with the epidrugs, zebularine and TSA, led to enrichment of the histone modification, H3K9Ac, associated with active genes, and depletion of the modification, H3K27me3, associated with silent genes and re-expression of HMGA-targeting miRNA. Moreover, epidrugs challenges were also associated with a concomitant decrease in hmga1 transcript and protein levels and concurrent increase in bmp-4 expression.
These findings show that the inverse relationship between HMGA expression and targeting miRNA is reversible through epidrug interventions. In addition to showing a mechanistic link between epigenetic modifications and miRNA expression these findings underscore their potential as therapeutic targets in this and other diseases.
KeywordsPituitary microRNA Chromatin Epidrugs HMGA1
We are grateful and wish to extend our thanks to Dr Kim Haworth for assistance with pyrosequencing. This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.
Conflict of interest
We hereby confirm that there is no financial or personal relationship between the authors and other people or organizations that can inappropriately influence the work and there is thereby no conflict of interest.
- 14.D’Angelo D, Palmieri D, Mussnich P, Roche M, Wierinckx A, Raverot G, Fedele M, Croce CM, Trouillas J, Fusco A (2012) Altered microRNA expression profile in human pituitary GH adenomas: down-regulation of miRNA targeting HMGA1, HMGA2, and E2F1. J Clin Endocrinol Metab 97(7):E1128–E1138. doi: 10.1210/jc.2011-3482 CrossRefPubMedGoogle Scholar
- 15.Palumbo T, Faucz FR, Azevedo M, Xekouki P, Iliopoulos D, Stratakis CA (2013) Functional screen analysis reveals miR-26b and miR-128 as central regulators of pituitary somatomammotrophic tumor growth through activation of the PTEN–AKT pathway. Oncogene 32(13):1651–1659. doi: 10.1038/onc.2012.190 PubMedCentralCrossRefPubMedGoogle Scholar
- 16.Gentilin E, Tagliati F, Filieri C, Mole D, Minoia M, Rosaria Ambrosio M, Degli Uberti EC, Zatelli MC (2013) miR-26a plays an important role in cell cycle regulation in ACTH-secreting pituitary adenomas by modulating protein kinase Cdelta. Endocrinology 154(5):1690–1700. doi: 10.1210/en.2012-2070 PubMedCentralCrossRefPubMedGoogle Scholar
- 24.Kramer MF (2011) Stem-loop RT-qPCR for miRNAs. In: Frederick M. Ausubel et al. (ed) Current protocols in molecular biology 15(15–10). doi: 10.1002/0471142727.mb1510s95
- 33.Pierantoni GM, Finelli P, Valtorta E, Giardino D, Rodeschini O, Esposito F, Losa M, Fusco A, Larizza L (2005) High-mobility group A2 gene expression is frequently induced in non-functioning pituitary adenomas (NFPAs), even in the absence of chromosome 12 polysomy. Endocr Relat Cancer 12(4):867–874. doi: 10.1677/erc.1.01049 CrossRefPubMedGoogle Scholar
- 34.Wang EL, Qian ZR, Yamada S, Rahman MM, Inosita N, Kageji T, Endo H, Kudo E, Sano T (2009) Clinicopathological characterization of TSH-producing adenomas: special reference to TSH-immunoreactive but clinically non-functioning adenomas. Endocr Pathol 20(4):209–220. doi: 10.1007/s12022-009-9094-y CrossRefPubMedGoogle Scholar
- 36.Baldassarre G, Fedele M, Battista S, Vecchione A, Klein-Szanto AJ, Santoro M, Waldmann TA, Azimi N, Croce CM, Fusco A (2001) Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway. Proc Natl Acad Sci USA 98(14):7970–7975. doi: 10.1073/pnas.141224998 PubMedCentralCrossRefPubMedGoogle Scholar
- 37.Fedele M, Battista S, Kenyon L, Baldassarre G, Fidanza V, Klein-Szanto AJ, Parlow AF, Visone R, Pierantoni GM, Outwater E, Santoro M, Croce CM, Fusco A (2002) Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene 21(20):3190–3198. doi: 10.1038/sj.onc.1205428 CrossRefPubMedGoogle Scholar
- 38.Fedele M, Pentimalli F, Baldassarre G, Battista S, Klein-Szanto AJ, Kenyon L, Visone R, De Martino I, Ciarmiello A, Arra C, Viglietto G, Croce CM, Fusco A (2005) Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene 24(21):3427–3435. doi: 10.1038/sj.onc.1208501 CrossRefPubMedGoogle Scholar
- 41.Yacqub-Usman K, Duong CV, Clayton RN, Farrell WE (2013) Preincubation of pituitary tumor cells with the epidrugs zebularine and trichostatin A are permissive for retinoic acid-augmented expression of the BMP-4 and D2R genes. Endocrinology 154(5):1711–1721. doi: 10.1210/en.2013-1061 CrossRefPubMedGoogle Scholar
- 42.Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, Setien F, Casado S, Suarez-Gauthier A, Sanchez-Cespedes M, Git A, Spiteri I, Das PP, Caldas C, Miska E, Esteller M (2007) Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 67(4):1424–1429. doi: 10.1158/0008-5472.CAN-06-4218 CrossRefPubMedGoogle Scholar
- 43.Rhodes LV, Nitschke AM, Segar HC, Martin EC, Driver JL, Elliott S, Nam SY, Li M, Nephew KP, Burow ME, Collins-Burow BM (2012) The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells. Oncol Rep 27(1):10–16. doi: 10.3892/or.2011.1488 PubMedCentralPubMedGoogle Scholar
- 45.Leone V, Langella C, D’Angelo D, Mussnich P, Wierinckx A, Terracciano L, Raverot G, Lachuer J, Rotondi S, Jaffrain-Rea ML, Trouillas J, Fusco A (2014) miR-23b and miR-130b expression is downregulated in pituitary adenomas. Mol Cell Endocrinol 390(1–2):1–7. doi: 10.1016/j.mce.2014.03.002 CrossRefPubMedGoogle Scholar
- 46.Bottoni A, Zatelli MC, Ferracin M, Tagliati F, Piccin D, Vignali C, Calin GA, Negrini M, Croce CM, Degli Uberti EC (2007) Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas. J Cell Physiol 210(2):370–377. doi: 10.1002/jcp.20832 CrossRefPubMedGoogle Scholar